Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology
This is a translation of a press release in Swedish published December 21, 2020
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the company has established a Scientific Advisory Board consisting of three leading scientists in the fields of clinical cardiology and immunology. The group enables an efficient and comprehensive knowledge transfer to Kancera from the research front and can thus contribute to high quality and accuracy in the company's clinical studies.
“We are proud and honored by the interest shown by these internationally leading scientists in Kancera and in our Fractalkine project. They will provide comprehensive expertise and scientific guidance within our core areas. The members' knowledge is particularly valuable in the planning and design of future clinical trials to reveal the medical and commercial potential for Kancera's drug candidates in the best way.” says Thomas Olin, CEO of Kancera AB.
The members of the Scientific Advisory Board participate as independent scientists and thus do not represent their institutions in this role. They are:
Petter Brodin, Associate Professor of Systems Immunology at Science for Life Laboratory and physician at the Karolinska Hospital.
Peter Libby, Professor of Medicine at Harvard Medical School and physician at Brigham and Women's Hospital, specializing in cardiovascular medicine.
Ioakim Spyridopoulos, Professor of Cardiovascular Gerontology at Newcastle University and Physician at Freeman Hospital, specializing in the treatment of acute heart attack.
About Kancera AB (publ)
Kancera AB conducts research and drug development within Karolinska Institutet Science Park in Stockholm in order to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. The stock is traded on NASDAQ First North Premier. FNCA Sweden AB is the company's Certified Adviser. FNCA can be reached at firstname.lastname@example.org and on 08-528 00 399. Charlotte Edenius, MD PhD, Anders Gabrielsen, MD PhD, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors as well as board members of Kancera AB.
For further information, please contact,
Thomas Olin, CEO: +46-735-20 40 41
Kancera AB (publ)
Karolinska Institutet Science Park
Nanna Svartz Väg 4
SE 171 65 Solna
Please visit the company's website; https://www.kancera.com